Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 10, 2010, Pages 753-768

  Mas Moruno, Carlos ^a   Rechenmacher, Florian ^a   Kessler, Horst ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Conformational restriction; Cyclization; Glioblastoma; Integrin antagonists; N methylation; RGD peptides; v 3

Indexed keywords

ALPHAVBETA1 INTEGRIN; ALPHAVBETA5 INTEGRIN; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CETUXIMAB; CILENGITIDE; CISPLATIN; FLUOROURACIL; GEMCITABINE; INTEGRIN; NAVELBINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADVANCED CANCER; AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN CANCER; BRAIN HEMORRHAGE; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL ADHESION; CHILDHOOD CANCER; CYCLIZATION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; IC 50; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PANCREAS CANCER; PLASMA CONCENTRATION-TIME CURVE; PONTINE GLIOMA; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN MOTIF; RECURRENT CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; TUMOR BLEEDING; TUMOR VASCULARIZATION;

EID: 79952741178     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010794728639     Document Type: Article

References (145)

1. Hynes, R.O. Integrins: Bidirectional, allosteric signaling machines. Cell, 2002, 110, 673-687.
2. Humphries, J. D.; Byron, A.; Humphries, M. J. Integrin ligands at a glance. J. Cell Sci., 2006, 119, 3901-3903.
3. Cox, D.; Brennan, M.; Moran, N. Integrins as therapeutic targets: lessons and opportunities. Nat. Rev. Drug Discov., 2010, 9, 804-820.
4. Arndt, T.; Arndt, U.; Reuning, U.; Kessler, H. In: Cancer Therapy: Molecular Targets in Tumor Host Interactions. Weber, G. F., Ed.; Horizon Bioscience, Norfolk, United Kingdom, 2005, pp. 93-141.
5. Jin, H.; Varner, J. Integrins: Roles in cancer development and as treatment agents. Br. J. Cancer, 2004, 90, 561-565.
6. Avraamides, C. J.; Garmy-Susini, B.; Varner, J. Integrins in angiogenesis and lymphangiogenesis. A. Nat. Rev. Cancer, 2008, 8, 604-617.
7. Desgrosellier, J. S.; Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer, 2010, 9, 9-22.
8. Plow, E. F.; Haas, T. A.; Zhang, L.; Loftus, J.; Smith, J. W. Ligand binding to integrins. J. Biol. Chem., 2000, 275, 21785-21788.
9. 3 integrin for a new cancer therapy. Angew. Chem. Int. Ed. Engl. 1997, 36, 1374-1389.
10. Heckmann, D.; Kessler, H. Design and chemical synthesis of integrin ligands. Method. Enzymol., 2007, 426, 463-503.
11. Xiong, J. P.; Stehle, T.; Diefenbach, B.; Zhang, R.; Dunker, R.; Scott, D.; Joachimiak, A.; Goodman, S. L.; Arnaout, M. A. Crystal structure of the extracellular segment of integrin αvβ3. Science, 2001, 294, 339-345.
12. Xiong, J. P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S. L.; Arnaout, M. A. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science, 2002, 296, 151-155.
13. Xiao, T.; Takagi, J.; Coller, B. S.; Wang, J. S.; Springer, T. A. Structural basis for allostery in integrins and binding to fibrinogenmimetic therapeutics. Nature, 2004, 432, 59-67.
14. Jonczyk, A.; Goodman, S.; Diefenbach, B.; Sutter, A.; Hölzemann, G.; Kessler, H.; Dechantsreiter, M. Preparation of cyclic peptides as integrin inhibitors. DE 19534177; EP 0770622; JP 1997132593; US 6001961.
15. Dechantsreiter, M. A.; Mathä, B.; Jonczyk, A.; Goodman, S. L.; Kessler, H. In: Peptides 1996, Proceedings of the 24th European Peptide Symposium, Edinburgh, Scotland, September 8-13, 1996; Ramage, R.; Epton, R.; Eds.; Mayflower Scientific Ltd.: England, 1998, pp. 329-330.
16. Dechantsreiter, M. A.; Planker, E.; Mathä, B.; Lohof, E.; Hölzemann, G.; Jonczyk, A.; Goodman, S. L.; Kessler, H. NMethylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists. J. Med. Chem. 1999, 42, 3033-3040.
17. Tabatabai, G.; Weller, M.; Nabors, B.; Picard, M.; Reardon, D.; Mikkelsen, T.; Ruegg, C.; Stupp, R. Targeting integrins in malignant glioma. Target. Oncol., 2010, 5, 175-181
18. Pierschbacher, M. D.; Hayman, E. G.; Ruoslahti, E. Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. Cell, 1981, 26, 259-267.
19. Pierschbacher, M. D.; Ruoslahti, E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature, 1984, 309, 30-33.
20. Pierschbacher, M. D.; Ruoslahti, E. Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc. Natl. Acad. Sci. USA, 1984, 81, 5985-5988.
21. Pytela, R.; Pierschbacher, M. D.; Ruoslahti, E. Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell, 1985, 40, 191-198.
22. Tamkun, J. W.; DeSimone, D. W.; Fonda, D.; Patel, R. S.; Buck, C.; Horwitz, A. F.; Hynes, R. O. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell, 1986, 46, 271-282.
23. Ruoslahti, E.; Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins. Science, 1987, 238, 491-497.
24. Albelda, S. M.; Buck, C. A. Integrins and other cell adhesion molecules. FASEB J., 1990, 4, 2868-2880.
25. Humphries, M. J. The molecular basis and specificity of integrinligand interactions. J. Cell Sci. 1990, 97, 585-592.
26. Ruoslahti, E. Integrins. J. Clin. Invest. 1991, 87, 1-5.
27. Pierschbacher, M. D.; Ruoslahti, E. Arg-Gly-Asp: A versatile cell recognition signal. Cell, 1986, 44, 517-518.
28. Wilson, I. A.; Haft, D. H.; Getzoff, E. D.; Tainer, J. A.; Lerner, R. A.; Brenner, S. Identical short peptide sequences in unrelated proteins can have different conformations: A testing ground for theories of immune recognition. Proc. Natl. Acad. Sci. USA, 1985, 82 ̧ 5255-5259.
29. Kessler, H. Conformation and biological activity of cyclic peptides. Angew. Chem. Int. Ed., 1982, 21, 512-523.
30. Hruby, V. J. Conformational restrictions of biologically active peptides via amino acid side chain groups. Life Sci., 1982, 31, 189-199.
31. Pierschbacher, M. D.; Ruoslahti, E. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J. Biol. Chem., 1987, 262, 17924-l7928.
32. Calvete, J. J.; Schafer, W.; Soszka, T.; Lu, W.; Cook, J. J.; Jameson, B. A.; Niewiarowski, S. Identification of the disulfide bond pattern in albolabrin, an RGD-containing peptide from the venom of Trimeresurus albolabris: significance for the expression of platelet aggregation inhibitory activity. Biochemistry, 1991, 30, 5225-5229.
33. Aumailley, M.; Gurrath, M.; Müller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic peptides: Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett., 1991, 291, 50-54.
34. Gurrath, M.; Müller, G.; Kessler, H.; Aumailley, M.; Timpl, R. Conformation/activity studies of rationally designed potent antiadhesive RGD peptides. Eur. J. Biochem., 1992, 210, 911-921.
35. Kessler, H.; Kutscher, B.; Klein, A. NMR-Studien zur Konformation von Cyclopentapeptidanalogen des Thymopoietins. Liebigs Ann. Chem., 1986, 893-913.
36. Kessler, H.; Gratias, R.; Hessler, G.; Gurrath, M.; Müller, G. Conformation of cyclic peptides. Principle concepts and the design of selectivity and superactivity in bioactive sequences by 'spatial screening'. Pure Appl. Chem., 1996, 68, 1201-1205.
37. Weide, T.; Modlinger, A.; Kessler, H. Spatial screening for the identification of the bioactive conformation of integrin ligands. Top. Curr. Chem., 2007, 272, 1-50.
38. Tranqui, L.; Andrieux, A.; Hudry-Clergeon, G.; Ryckewaert, J. J.; Soyez, S.; Chapel, A.; Ginsberg, M. H.; Plow, E. F.; Marguerie, G. Differential structural requirements for fibrinogen binding to platelets and to endothelial cells. J. Cell Biol., 1989, 108, 2519-2527.
39. Müller, G.; Gurrath, M.; Kessler, H.; Timpl, R. Dynamic forcing, a method for evaluating activity and selectivity profiles of RGD (Arg-Gly-Asp) peptides. Angew. Chem. Int. Ed. Engl., 1992, 31, 326-328.
40. Pfaff, M.; Tangemann, K.; Müller, B.; Gurrath, M.; Müller, G.; Kessler, H.; Timpl, R.; Engel, J. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J. Biol. Chem., 1994, 269, 20233-20238.
41. Müller, G.; Gurrath, M.; Kessler, H. Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides. J. Comp-Aided Mol. Des., 1994, 8, 709-730.
42. Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman, S. L.; Jonczyk, A.; Kessler, H. Structural and functional aspects of RGDcontaining cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists. J. Am. Chem. Soc., 1996, 118, 7461-7472.
43. Brooks, P. C.; Montgomery, A. M.; Rosenfeld, M.; Reisfeld, R. A.; Hu, T.; Klier, G.; Cheresh, D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994, 79, 1157-1164.
44. Hersel, U.; Dahmen, C.; Kessler, H. RGD modified polymers: Biomaterials for stimulated cell adhesion and beyond. Biomaterials, 2003, 24, 4385-4415.
45. López-García, M.; Kessler, H. In: Handbook of Biomineralization. Epple, M.; Bäuerlein, E. Eds.; Wiley, Weinheim, 2007, pp. 109-126.
46. Schottelius, M.; Laufer, B.; Kessler, H.; Wester, H. J. Ligands for mapping αvβ3-integrin expression in vivo. Accounts Chem. Res., 2009, 42, 969-980.
47. Geyer, A.; Mierke, D. F.; Unverzagt, C.; Kessler, H. In: Peptides 1992, Proceedings of the 22nd European Peptide Symposium, Interlaken, Switzerland, September 13-19, 1992; Schneider, C. H.; Eberle, A. N., Eds.; ESCOM Science Publishers, Leiden, Netherlands, 1993, pp. 599-600.
48. Geyer, A.; Müller, G.; Kessler, H. Conformational-analysis of a cyclic Rgd peptide-containing a Psi[CH2-NH] bond-a positional shift in backbone structure caused by a single dipeptide mimetic. J. Am. Chem. Soc., 1994, 116, 7735-7743.
49. Haubner, R.; Schmitt, W.; Hölzemann, G.; Goodman, S. L.; Jonczyk, A.; Kessler, H. Cyclic RGD peptides containing beta-turn mimetics. J. Am. Chem. Soc., 1996, 118, 7881-7891.
50. Lohof, E.; Planker, E.; Mang, C.; Burkhart, F.; Dechantsreiter, M.A.; Haubner, R.; Wester, H. J.; Schwaiger, M.; Hölzemann, G.; Goodman, S. L.; Kessler, H. Carbohydrate derivatives for use in drug design: Cyclic alpha(v)-selective RGD peptides. Angew. Chem. Int. Ed., 2000, 39, 2761-2764.
51. Wermuth, J.; Goodman, S. L.; Jonczyk, A.; Kessler, H. Stereoisomerism and biological activity of the selective and superactive alpha(v)beta(3) integrin inhibitor cyclo(-RGDfV-) and its retroinverso peptide. J. Am. Chem. Soc., 1997, 119, 1328-1335.
52. Keenan, R. M.; Miller, W. H.; Kwon, C.; Ali, F. E.; Callahan, J. F.; Calvo, R. R.; Hwang, S. M.; Kopple, K. D.; Peishoff, C. E.; Samanen, J. M.; Wong, A. S.; Yuan, C. K.; Huffman, W. F. Discovery of potent nonpeptide vitronectin receptor (αvβ3) antagonists. J. Med. Chem., 1997, 40, 2289-2292.
53. Chatterjee, J.; Gilon, C.; Hoffman, A.; Kessler, H. N-methylation of peptides: a new perspective in Medicinal chemistry. Accounts Chem. Res., 2008, 41, 1331-1342.
54. Doedens, L.; Opperer, F.; Cai, M.; Beck, J. G.; Dedek, M.; Palmer, E.; Hruby, V. J.; Kessler, H. Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies. J. Am. Chem. Soc., 2010, 132, 8115-8128.
55. Biron, E.; Chatterjee, J.; Ovadia, O.; Langenegger, D.; Brueggen, J.; Hoyer, D.; Schmid, H. A.; Jelinek, R.; Gilon, C.; Hoffman, A.; Kessler, H. Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogs. Angew. Chem. Int. Ed., 2008, 47, 2595-2599.
56. Ovadia, O.; Greenberg, S.; Laufer, B.; Gilon, C.; Hoffman, A.; Kessler, H. Improvement of drug-like properties of peptides: the somatostatin paradigm. Expert Opin. Drug Discov., 2010, 5, 655-671
57. Chatterjee, J.; Mierke, D.; Kessler, H. N-Methylated cyclic pentaalanine peptides as template structures. J. Am. Chem. Soc., 2006, 128, 15164-15172.
58. Chatterjee, J.; Mierke, D. F.; Kessler, H. Conformational preference and potential templates of N-methylated cyclic pentaalanine peptides. Chem. Eur. J., 2008, 14, 1508-1517.
59. Tonelli, A. E. The effects of isolated N-methylated residues on the conformational characteristics of polypeptides. Biopolymers, 1976, 15, 1615-1622.
60. Manavalan, P.; Momany, F. A. Conformational energy studies on N-methylated analogues of thyrotropin releasing hormone, enkephalin and luteinizing hormone releasing hormone. Biopolymers, 1980, 19, 1943-1973.
61. Haviv, F.; Fitzpatrick, T. D.; Swenson, R. E.; Nichols, C. J.; Mort, N. A.; Bush, E. N.; Diaz, G.; Bammert, G.; Nguyen, A.; Rhutasel, N. S.; Nellans, H. N.; Hoffman, D. J.; Johnson, E. S.; Greer, J. Effect of N-methyl substitution of the peptide-bonds in luteinizing hormone releasing hormone agonists. J. Med. Chem., 1993, 36, 363-369.
62. Wormser, U.; Laufer, R.; Hart, Y.; Chorev, M.; Gilon, C.; Selinger, Z. Highly selective agonists for substance P receptor subtypes. EMBO J., 1986, 5, 2805-2808.
63. Ron, D.; Gilon, C.; Hanani, M.; Vromen, A.; Selinger, Z.; Chorev, M. N-Methylated analogues of Ac[Nle28,31]CCK(26-33). J. Med. Chem., 1992, 35, 2806-2811.
64. Bach II, A.C.; Eyermann, C. J.; Gross, J. D.; Bower, M. J.; Harlow, R. L.; Weber, P. C.; DeGrado, W. F. Structural studies of a family of high affinity ligands for GPIIb/IIIa J. Am. Chem. Soc., 1994, 116, 3207-3219.
65. Bach II, A. C.; Eyermann, C. J.; Gross, J. D.; Bower, M. J.; Harlow, R. L.; Weber, P. C.; DeGrado, W. F. Structural studies of a family of high affinity ligands for GPIIb/IIIa J. Am. Chem. Soc.,1994, 116, 3207-219.
66. Müller, G. The β turn as a selectivity switch: βI or βII'? That is the question. Angew. Chem. Int. Ed. Eng., 1996, 35, 2767-2769.
67. Eilken, H.M.; Adams, R.H. Turning on the angiogenic microswitch. Nat. Med., 2010, 16, 853-854.
68. Guo, W.J.; Giancotti, F.G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol., 2004, 5, 816-826.
69. Humphries, M.J. Integrin structure. Biochem. Soc. Trans., 2000, 28, 311-340.
70. Hood, J.D.; Cheresh, D.A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer, 2002, 2, 91-100.
71. Adams, R.H; Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol., 2007, 8, 464-478.
72. Shattil, S.J.; Kim, C.; Ginsberg, M.H. The final steps of integrin activation: the end game. Nat. Rev. Mol. Cell Biol., 2010, 11, 288-300.
73. Hynes, R.O. A reevaluation of integrins as regulators of angiogenesis. Nat. Med., 2002, 8, 918-921.
74. Frisch, S.M.; Screaton, R.A. Anoikis mechanisms. Curr. Opin. Cell Biol., 2001, 13, 555-562.
75. Frisch, S.M.; Ruoslahti, E. Integrins and anoikis. Curr. Opin. Cell Biol., 1997, 9, 701-706.
76. Rytömaa, M.; Martins, L.M.; Downward, J. Involvement of FADD and caspase-8 signalling in detachment-induced apoptosis. Curr. Biol., 1999, 9, 1043-1046.
77. Stupack, D.G.; Puente, X.S.; Boutsaboualoy, S.; Storgard, C.M.; Cheresh, D.A. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J. Cell Biol., 2001, 155, 459-470.
78. Cheresh, D.A.; Stupack, D.G. Integrin-mediated death: An explanation of the integrin-knockout phenotype? Nat. Med., 2002, 8, 193-194.
79. Stupack, D.G.; Cheresh, D.A. A Bit-role for integrins in apoptosis. Nat. Cell Biol., 2004, 6, 388-389.
80. Mould, A.P.; Humphries, M.J. Cell biology - Adhesion articulated. Nature, 2004, 432, 27-28.
81. Marinelli, L.; Gottschalk, K.-E.; Meyer, A.; Novellino, E.; Kessler, H. Human integrin αvβ5: Homology modeling and ligand binding. J. Med. Chem., 2004, 47, 4166-4177.
82. Marinelli, L.; Meyer, A.; Heckmann, D.; Lavecchia, A.; Novellino, E.; Kessler, H. Ligand binding analysis for human α5β1 integrin: Strategies for designing new α5β1 antagonists. J. Med. Chem., 2005, 48, 4204-4207.
83. Heckmann, D.; Meyer, A.; Marinelli, L.; Zahn, G.; Stragies, R.; Kessler H. Probing integrin selectivity: Rational design of highly active and selective ligands for the α5β1 and αvβ3 integrin receptor. Angew. Chemie Int. Ed. 2007, 46, 3571-3574.
84. Ruoslahti, E. Specialization of tumour vasculature. Nat. Rev. Cancer, 2002, 2, 83-90.
85. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1, 27-31.
86. Holmgren, L.; Oreilly, M.S.; Folkman, J. Dormancy of micrometastases - balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1995, 1, 149-153.
87. Harris, A.L. Hypoxia - A key regulatory factor in tumour growth. Nat. Rev. Cancer, 2002, 2, 38-47.
88. Ferrara, N.; Hillan, K.J.; Gerber, H.P.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov., 2004, 3, 391-400.
89. Brooks, P.C.; Clark, R.A.F.; Cheresh, D.A. Requirement of vascular integrin αvβ3 for angiogenesis. Science, 1994, 264, 569-571.
90. Ruegg, C.; Mariotti, A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell. Mol. Life Sci., 2003, 60, 1135-1157.
91. Haubner, R.; Weber, W.A.; Beer, A.J.; Vabuliene, E.; Reim, D.; Sarbia, M.; Becker, K.F.; Goebel, M.; Hein, R.; Wester, H.J.; Kessler, H.; Schwaiger, M. Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [F-18]Galacto-RGD. Plos Med., 2005, 2, 244-252.
92. Beer, A.J.; Haubner, R.; Sarbia, M.; Goebel, M.; Luderschmidt, S.; Grosu, A.L.; Schnell, O.; Niemeyer, M.; Kessler, H.; Wester, H.-J.; Weber, W.A.; Schwaiger, M. Positron emission tomography using [F-18]Galacto-RGD identifies the level of integrin αvβ3 expressionin man. Clin. Cancer Res., 2006, 12, 3942-3949.
93. Felding-Habermann, B.; O'Toole, T.E.; Smith, J.W.; Fransvea, E.; Ruggeri, Z.M.; Ginsberg, M.H.; Hughes, P.E.; Pampori, N.; Shattil, S.J.; Saven, A.; Mueller, B.M. Integrin activation controls metastasis in human breast cancer. Proc. Natl Acad. Sci., USA, 2001, 98, 1853-1858.
94. Mignatti, P.; Rifkin, D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev., 1993, 73, 161-195.
95. Deryugina, E.I.; Bourdon, M.A.; Luo, G.X.; Reisfeld, R.A.; Strongin, A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J. Cell Sci., 1997, 110, 2473-2482.
96. Schnell, O.; Krebs, B.; Wagner, E.; Romagna, A.; Beer, A.J.; Grau, S.J.; Thon, N.; Goetz, C.; Kretzschmar, H.A.; Tonn, J.C.; Goldbrunner, R.H. Expression of integrin αvβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol., 2008, 18, 378-386.
97. Bello, L.; Francolini, M.; Marthyn, P.; Zhang, J.P.; Carroll, R.S.; Nikas, D.C.; Strasser, J.F.; Villani, R.; Cheresh, D.A.; Black, P.M. αvβ3 and αvβ5 integrin expression in glioma periphery. Neurosurgery, 2001, 49, 380-389.
98. Bader, B.L.; Rayburn, H.; Crowley, D.; Hynes, R.O. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins Cell, 1998, 95, 507-519.
99. Reynolds, L.E.; Wyder, L.; Lively, J.C.; Taverna, D.; Robinson, S.D.; Huang, X.Z.; Sheppard, D.; Hynes, O.; Hodivala-Dilke, K.M. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat. Med., 2002, 8, 27-34.
100. Hynes, R.O.; Hodivala-Dilke, K.M. Insights and questions arising from studies of a mouse model of Glanzmann thrombasthenia. Thromb. Haemost., 1999, 82, 481-485.
101. Tomiyama, Y. Glanzmann thrombasthenia: Integrin αIIbβ3 deficiency. Int. J. Hematol., 2000, 72, 448-454.
102. Carmeliet, P. Integrin indecision. Nat. Med., 2002, 8, 14-16.
103. Kim, S.; Bell, K.; Mousa, S.A.; Varner, J.A. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cellbinding domain of fibronectin. Am J. Pathol., 2000, 156, 1345-1362.
104. Yang, J.Z.; Rayburn, H.; Hynes, R.O. Embryonic mesodermal defects in α5 integrin-deficient mice. Development, 1993, 119, 1093-1105.
105. Francis, S.E.; Goh, K.L.; Hodivala-Dilke, K.; Bader, B.L.; Stark, M.; Davidson, D.; Hynes, R.O. Central roles of α5beta;1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 927-933.
106. Friedlander, M.; Brooks, P.C.; Shaffer, R.W.; Kincaid, C.M.; Varner, J.A.; Cheresh, D.A. Definition of 2 angiogenic pathways by distinct αv integrins. Science, 1995, 270, 1500-1502.
107. Boudreau, N.J.; Varner, J.A. The homeobox transcription factor Hox D3 promotes integrin α5β1 expression and function during angiogenesis. J. Biol. Chem., 2004, 279, 4862-4868.
108. Kerr, J.S.; Slee, A.M.; Mousa, S.A. The αv integrin antagonists as novel anticancer agents: an update. Exp. Opin. Invest. Drugs, 2002, 11, 1765-1774.
109. Koch, A.E. Angiogenesis as a target in rheumatoid arthritis. Annu. Rheum. Dis., 2003, 62, 60-67.
110. Meredith, J.E.; Fazeli, B.; Schwartz, M.A. The extracellular-matrix as a cell-survival factor. Mol. Biol. Cell, 1993, 4, 953-961.
111. Varner, J.A.; Emerson, D.A.; Juliano, R.L. Integrin α5β1 expression negatively regulates cell-growth - reversal by attachment to fibronectin. Mol. Biol. Cell, 1995, 6, 725-740.
112. Meyer, A.; Auernheimer, J.; Modlinger, A.; Kessler, H. Targeting RGD recognizing integrins: Drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des., 2006, 12, 2723-2747.
113. Taga, T.; Suzuki, A.; Gonzalez-Gomez, I.; Gilles, F.H.; Stins, M.; Shimada, H.; Barsky, L.; Weinberg, K.I.; Laug, W.E. Alpha vintegrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int. J. Cancer, 2002, 98, 690-697.
114. Paolillo, M.; Russo, M.A.; Serra, M.; Colombo, L.; Schinelli, S. Small molecule integrin antagonists in cancer therapy. Mini-Rev. Med. Chem. 2009, 9, 1439-1446.
115. Mitjans, F.; Meyer, T.; Fittschen, C.; Goodman, S.; Jonczyk, A.; Marshall, J.F.; Reyes, G.; Piulats, J. In vivo therapy of malignant melanoma by means of antagonists of αv integrins. Int. J. Cancer, 2000, 87, 716-723.
116. MacDonald, T.J.; Taga, T.; Shimada, H.; Tabrizi, P.; Zlokovic, B.V.; Cheresh, D.A.; Laug, W.E. Preferential susceptibility of brain tumors to the antiangiogenic effects of an αv integrin antagonist. Neurosurgery, 2001, 48, 151-157.
117. Buerkle, M.A.; Pahernik, S.A.; Sutter, A.; Jonczyk, A.; Messmer, K.; Dellian, M. Inhibition of the alpha-v integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br. J. Cancer, 2002, 86, 788-795.
118. Smith, J.W. Cilengitide (Merck). Curr. Opin. Invest. Drugs, 2003, 4, 741-745.
119. Monnier, Y.; Farmer, P.; Bieler, G.; Imaizumi, N.; Sengstag, T.; Alghisi, G.C.; Stehle, J.C.; Ciarloni, L.; Andrejevic-Blant, S.; Moeckli, R.; Mirimanoff, R.O.; Goodman, S.L.; Delorenzi, M.; Ruegg, C. CYR61 and αvβ5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res., 2008, 68, 7323-7331.
120. B̈uerle, T.; Komljenovic, D.; Merz, M.; Berger, M. R.; Goodman, S.L.; Semmler, W. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int. J. Cancer, n/a. doi: 10.1002/ijc.25563. Early view (article first published online on July 20th 2010).
121. Skuli, N.; Monferran, S.; Delmas, C.; Favre, G.; Bonnet, J.; Toulas, C.; Moyal, E.C.J. αvβ3/αvβ5 Integrins-FAK-RhoB: A novel pathway for hypoxia regulation in glioblastoma. Cancer Res., 2009, 69, 3308-3316.
122. Reynolds, A.R.; Hart, I.R.; Watson, A.R.; Welti, J.C.; Silva, R.G.; Robinson, S.D.; Da Violante, G.; Gourlaouen, M.; Salih, M.; Jones, M.C.; Jones, D.T.; Saunders, G.; Kostourou, V.; Perron-Sierra, F.; Norman, J.C.; Tucker, G.C.; Hodivala-Dilke, K.M. Stimulation of tumor growth and angiogenesis by low concentrations of RGDmimetic integrin inhibitors. Nat. Med., 2009, 15, 392-400.
123. Weller, M.; Reardon, D.; Nabors, B.; Stupp, R. Will integrin inhibitors have proangiogenic effects in the clinic? Nat. Med., 2009, 15, 726-726.
124. Reynolds, A.R.; Hodivala-Dilke, K.M. Will integrin inhibitors have proangiogenic effects in the clinic? Reply. Nat. Med., 2009, 15, 727-727.
125. Raguse, J.-D.; Gath, H.J.; Bier, J.; Riess, H.; Oettle, H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol., 2004, 40, 228-230.
126. Albert, J.M.; Cao, C.; Ling, G.; Leavitt, L.; Hallahan, D.E.; Bo, L. Integrin αvβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 1536-1543.
127. Abdollahi, A.; Griggs, D.W.; Zieher, H.; Roth, A.; Lipson, K.E.; Saffrich, R.; Grone, H.J.; Hallahan, D.E.; Reisfeld, R.A.; Debus, J.; Niethammerl, A.G.; Huber, P.E. Inhibition of αvβ3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin. Cancer Res., 2005, 11, 6270-6279.
128. Nabors, B. L.; Mikkelsen, T.; Rosenfeld, S. S.; Hochberg, F.; Akella, N. S.; Fisher J. D.; Cloud G. A.; Zhang, Y.; Carson, K.; Wittemer, S. M.; Colevas, D.; Grossman S. A. A phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 2007, 25, 1651-1657.
129. Eskens, F. A. L. M.; Dumez, H.; Hoekstra, R.; Perschlc, A.; Brindley, C.; Böttcher, S.; Wynendaele, W.; Drevs, J.; Verweij, J.; van Oosterom, A. T. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur. J. Cancer, 2003, 39, 917-926.
130. Hariharan, S.; Gustafson, D.; Holden, S.; McConkey, D.; Davis, D.; Morrow, M.; Basche, M.; Gore, L.; Zang, C.; O'Bryant, L.; Baron, A.; Gallemann, D.; Colevas, D.; Eckhardt, S. G. Assessment of the biological and pharmacological effects of the avb3 and avb5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann. Oncol., 2007, 18, 1400-1407.
131. MacDonald, T. J.; Stewart, C. F.; Kocak, M.; Goldman, S.; Ellenbogen, R. G.; Phillips, P.; Lafond, D.; Poussaint, T. Y.; Kieran, M. W.; Boyett, J. M.; Kun, L. E. Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012. J. Clin. Oncol., 2008, 26, 919-924.
132. Stupp, R.; Ruegg, C. Integrin inhibitors reaching the clinic. J. Clin. Oncol., 2007, 25, 1637-1638.
133. Gilbert, M.; Lamborn, K.; Lassman, A.; Cloughesy, T.; Chang, S.; Lieberman, F.; Wen, P.; Poetzsch, S.; Picard, M.; Prados, M.; Kuhn, J. Tumor tissue delivery of cilengitide after intravenous administration to patients with recurrent glioblastoma. Preliminary data from NABTC protocol 03-02. Neuro Oncol., 2007, 9, 525.
134. Reardon, D. A.; Fink, K. L.; Mikkelsen, T.; Cloughesy, T. F.; O'Neill, A.; Plotkin, S.; Glantz, M.; Ravin, P.; Raizer, J. J.; Rich, K. M.; Schiff, D.; Shapiro, W. R.; Burdette-Radoux, S.; Dropcho, E. J.; Wittemer, S. M.; Nippgen, J.; Picard, M.; Nabors, L. B. Randomized phase II study of cilengitide, an integrintargeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol., 2008, 26, 5610-5617.
135. Fink, K.; Mikkelsen, T.; Nabors, L. B.; Ravin, P.; Plotkin, S. R.; Schiff, D.; Hicking, C.; Picard, M.; Reardon, D. A. Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: a randomized phase IIa study. J. Clin. Oncol., 2010, 28, 15s (suppl; abstr 2010).
136. Nabors, L.; Mikkelsen, T.; Batchelor, T.; Lesser, G.; Rosenfeld, M.; Ye, X.; Piantadosi, S.; Olson, J.; Brem, S.; Grossman, S. A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). J. Clin. Oncol. 2009, 27, 15s (suppl; abstr 2001).
137. Stupp, R.; Hegi, M. E.; Neyns, B.; Goldbrunner, R.; Schlegel, U.; Clement, P. M.; Grabenbauer, G. G.; Ochsenbein, A. F.; Simon, M.; Dietrich, P. Y.; Pietsch, T.; Hicking, C.; Tonn, J. C.; Diserens, A. C.; Pica, A.; Hermisson, M.; Krueger, S.; Picard, M.; Weller, M. J. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Clin. Oncol., 2010, 28, 2712-2718.
138. Hegi, M. E.; Diserens, A. C.; Gorlia, T.; Hamou, M. F.; de Tribolet, N.; Weller, M.; Kros, J. M.; Hainfellner, J. A.; Mason, W.; Mariani, L.; Bromberg, J. E.; Hau, P.; Mirimanoff, R. O.; Cairncross, J. G.; Janzer, R. C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 2005, 352, 997-1003.
139. Stupp, R; Van Den Bent, M. J.; Erridge, S. C.; Reardon, D. A.; Hong, Y.; Wheeler, H.; Hegi, M.; Perry, J. R.; Picard, M.; Weller, M. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, openlabel, controlled phase III trial (CENTRIC). J. Clin. Oncol. 2010, 28, 15s (suppl; abstr TPS152).
140. ClinicalTrials.gov http://www.clinicaltrials.gov (Accessed December 2010).
141. Nabors, L. B.; Fink, K.; Reardon, D. A.; Lesser, G. J.; Trusheim, J.; Raval, S. N.; Hicking, C.; Picard, M.; Mikkelsen, T. Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: Protocol of a multicenter, randomized, open-label, controlled phase II study. J. Clin. Oncol. 2010, 28, 15s (suppl; abstr TPS151).
142. Friess, H.; Langrehr, J. M.; Oettle, H.; Raedle, J.; Niedergethmann, M.; Dittrich, C.; Hossfeld, D. K.; Stöger, H.; Neyns, B.; Herzog, P.; Piedbois, P.; Dobrowolski, F.; Scheithauer, W.; Hawkins, R.; Katz, F.; Balcke, P.; Vermorken, J.; van Belle, S.; Davidson, N.; Esteve, A. A.; Castellano, D.; Kleeff, J.; Tempia-Caliera, A. A.; Kovar, A.; Nippgen, J. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer, 2006, 6, 285.
143. The Merck group. Merck's news release. June 5, 2010. http://www. merck.de (Accessed December 2010).
144. Beekman, K. W.; Colevas, A. D.; Cooney, K.; Dipaola, R.; Dunn, R. L.; Gross, M.; Keller, E. T.; Pienta, K. J.; Ryan, C. J.; Smith, D.; Hussain, M. Phase II evaluations of Cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin. Genitourin. Cancer, 2006, 4, 299-302.
145. Bradley, D. A.; Dunn, R.; Ryan, C.; DiPaola, R.; Smith, D. C.; Cooney, K. A.; Mathew, P.; Gross, M.; Colevas, A. D.; Hussain, M. EMD121974 (NSC 707544, cilengitide) in asymptomatic metastatic androgen independent prostate cancer (AIPCa) patients (pts): A randomized trial by the Prostate Cancer Clinical Trials Consortium (NCI 6372) J. Clin. Oncol. 2007, 25, 18s (suppl; abstr 5137).